Vetr upgraded shares of Illumina Inc. (NASDAQ:ILMN) from a hold rating to a strong-buy rating in a report published on Tuesday. Vetr currently has $165.56 price target on the life sciences company’s stock.
A number of other research analysts also recently commented on ILMN. CL King initiated coverage on shares of Illumina in a research report on Tuesday, June 21st. They set a buy rating and a $165.00 target price on the stock. Cantor Fitzgerald reissued a hold rating on shares of Illumina in a research report on Wednesday, June 29th. Zacks Investment Research raised shares of Illumina from a sell rating to a hold rating in a research report on Monday, July 4th. Morgan Stanley downgraded shares of Illumina from an equal weight rating to an underweight rating and cut their target price for the company from $130.00 to $110.00 in a research report on Tuesday, July 5th. Finally, Piper Jaffray Cos. restated an overweight rating and issued a $161.00 price target on shares of Illumina in a report on Friday, July 15th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Illumina presently has an average rating of Hold and an average target price of $159.24.
Shares of Illumina (NASDAQ:ILMN) opened at 138.99 on Tuesday. Illumina has a 52 week low of $127.10 and a 52 week high of $196.47. The stock’s 50 day moving average is $174.01 and its 200 day moving average is $156.43. The stock has a market cap of $20.38 billion, a price-to-earnings ratio of 47.60 and a beta of 0.47.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. The business had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.80 EPS. On average, equities analysts forecast that Illumina will post $3.53 EPS for the current year.
In other news, Director Roy A. Whitfield sold 4,000 shares of the business’s stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $167.22, for a total transaction of $668,880.00. Following the transaction, the director now owns 6,853 shares of the company’s stock, valued at approximately $1,145,958.66. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction dated Friday, October 7th. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00. Following the transaction, the director now directly owns 17,065 shares in the company, valued at approximately $3,146,103.40. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Daiwa SB Investments Ltd. purchased a new position in shares of Illumina during the third quarter valued at $545,000. Private Asset Management Inc. boosted its position in shares of Illumina by 18.3% in the third quarter. Private Asset Management Inc. now owns 7,547 shares of the life sciences company’s stock valued at $1,371,000 after buying an additional 1,170 shares during the last quarter. Telemus Capital LLC boosted its position in shares of Illumina by 7.1% in the third quarter. Telemus Capital LLC now owns 2,242 shares of the life sciences company’s stock valued at $407,000 after buying an additional 149 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Illumina by 63.6% in the third quarter. BNP Paribas Arbitrage SA now owns 67,242 shares of the life sciences company’s stock valued at $12,215,000 after buying an additional 26,144 shares during the last quarter. Finally, Kentucky Retirement Systems Insurance Trust Fund purchased a new position in shares of Illumina during the second quarter valued at $834,000. 95.22% of the stock is currently owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.